Neutral, evidence-based, PubMed-cited breakdowns of how the most-searched peptides and metabolic compounds actually compare — mechanism, clinical-trial results, side effects, and regulatory status. Educational only; never sourcing or medical advice.
Retatrutide vs tirzepatide compared — receptor targets, clinical-trial weight loss, side effects, and FDA status. Evidence-based, PubMed-cited. Retatrutide remains investigational.
Read comparison
Retatrutide vs semaglutide (Ozempic/Wegovy) compared — receptor targets, clinical-trial weight loss, side effects, FDA status. Evidence-based, PubMed-cited. Retatrutide remains investigational.
Read comparison
Semaglutide (Ozempic/Wegovy) vs tirzepatide (Mounjaro/Zepbound) — the SURMOUNT-5 head-to-head trial, receptor targets, weight loss, and side effects. Evidence-based, PubMed-cited.
Read comparison
BPC-157 vs TB-500 compared honestly — proposed mechanisms, the (thin) human evidence, FDA status, and WADA bans. Both are unapproved research peptides. Evidence-based, cited.
Read comparisonThese pages are for educational purposes only and are not medical advice. PeptidePanel does not promote, source, or supply any compound. Investigational agents discussed here are not FDA-approved. Always consult a licensed clinician before making any treatment decision.